Atea Pharmaceuticals (NASDAQ:AVIR) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Institutional and Insider Ownership
70.4% of Atea Pharmaceuticals shares are owned by institutional investors. 18.4% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Atea Pharmaceuticals and Ono Pharmaceutical’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atea Pharmaceuticals||$48.63 million||44.65||-$10.95 million||($0.51)||-51.43|
|Ono Pharmaceutical||$2.92 billion||3.96||$708.99 million||$1.43||15.73|
Ono Pharmaceutical has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for Atea Pharmaceuticals and Ono Pharmaceutical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Atea Pharmaceuticals presently has a consensus price target of $55.75, suggesting a potential upside of 112.54%. Given Atea Pharmaceuticals’ higher possible upside, equities analysts plainly believe Atea Pharmaceuticals is more favorable than Ono Pharmaceutical.
This table compares Atea Pharmaceuticals and Ono Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ono Pharmaceutical beats Atea Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.